Raymond James Downgrades Aardvark Therapeutics to Market Perform
Raymond James has downgraded Aardvark Therapeutics, Inc. from its previous rating to Market Perform.
Stocks · News reference
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright Adjusts Price Target for Aardvark Therapeutics
HC Wainwright has lowered its price target for Aardvark Therapeutics from $4.00 to $2.00 while maintaining a Neutral rating.
FDA Lifts Clinical Hold on Aardvark Therapeutics' ARD-101
The U.S. Food and Drug Administration has lifted the clinical hold on Aardvark Therapeutics' investigational new drug application for ARD-101, intended for treating hyperphagia in Prader-Willi Syndrome.
Aardvark Therapeutics Reports Exploratory Data from Terminated HERO and OLE Trials
Aardvark Therapeutics released exploratory efficacy and safety data from its previously terminated Phase 3 HERO and open-label extension trials for ARD-101.
8-K filing — Aardvark Therapeutics, Inc. (AARD)
Filed: 2026-10-23 AccNo: 0001193125-26-429509 Size: 11 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
Aardvark Therapeutics reported exploratory efficacy data from its early-terminated Phase 3 HERO trial for ARD-101, a hunger-suppressing therapy for Prader-Willi syndrome. The drug showed modest reductions in hyperphagia scores and was generally well-tolerated, though one cardiac serious adverse event occurred at the highest dose in combination with another drug. The FDA lifted the clinical hold, allowing the company to resume development at lower doses and plan a new Phase 3 trial.